Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aslan Pharmaceuticals expects cash to fund operations through late 2023 » 07:04
10/26/21
10/26
07:04
10/26/21
07:04
ASLN

Aslan Pharmaceuticals

$1.39 /

-0.08 (-5.44%)

Cash and cash equivalents…

Cash and cash equivalents totalled $100.5M as of September 30, 2021, compared to US$94.1 million as of June 30, 2021, and $14.3M as of December 31, 2020. Management believes that ASLAN's cash and cash equivalents will be sufficient to fund operations through late 2023.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

Hot Stocks
Aslan Pharmaceuticals announces anticipated upcoming milestones » 07:03
10/26/21
10/26
07:03
10/26/21
07:03
ASLN

Aslan Pharmaceuticals

$1.39 /

-0.08 (-5.44%)

First patient enrolment…

First patient enrolment in global Phase 2b trial of ASLAN004 for AD expected in the fourth quarter of 2021. Initiation of Phase 2 trial of ASLAN003 in inflammatory bowel disease expected in the first half of 2022.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

Earnings
Aslan Pharmaceuticals reports Q3 EPS (12c), consensus (13c) » 07:03
10/26/21
10/26
07:03
10/26/21
07:03
ASLN

Aslan Pharmaceuticals

$1.39 /

-0.08 (-5.44%)

"This quarter, we…

"This quarter, we were pleased to announce positive data from our Phase 1 multiple ascending dose trial of ASLAN004, supporting the potential of this first-in-class antibody as a differentiated, novel treatment for atopic dermatitis," said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. "This quarter we also made key appointments to strengthen our management team and established a scientific advisory board comprised of global thought-leaders in dermatology and immunology. In addition, we expanded our US operations with a new office in Menlo Park, CA. We are entering the fourth quarter with strengthened operating position and poised to advance ASLAN004 in a 300-patient, Phase 2b trial before year-end, as well as advance our DHODH inhibitor, ASLAN003 into clinical trials early next year."

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

ASLN Aslan Pharmaceuticals
$1.39 /

-0.08 (-5.44%)

Conference/Events
Aslan Pharmaceuticals to hold an investor webinar » 09:55
10/25/21
10/25
09:55
10/25/21
09:55
ASLN

Aslan Pharmaceuticals

$1.48 /

+0.01 (+0.68%)

Management discusses the…

Management discusses the recently announced, positive topline data from the Company's randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for treatment of moderate-to-severe atopic dermatitis (AD) in an Investor Webinar to be held on October 25 at 10 am. Webcast Link

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.48 /

+0.01 (+0.68%)

ASLN Aslan Pharmaceuticals
$1.48 /

+0.01 (+0.68%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.48 /

+0.01 (+0.68%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.48 /

+0.01 (+0.68%)

ASLN Aslan Pharmaceuticals
$1.48 /

+0.01 (+0.68%)

Conference/Events
Aslan Pharmaceuticals to hold an investor webinar » 04:55
10/25/21
10/25
04:55
10/25/21
04:55
ASLN

Aslan Pharmaceuticals

$1.47 /

-0.12 (-7.55%)

Management discusses the…

Management discusses the recently announced, positive topline data from the Company's randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for treatment of moderate-to-severe atopic dermatitis (AD) in an Investor Webinar to be held on October 25 at 10 am. Webcast Link

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

Conference/Events
Aslan Pharmaceuticals to hold an investor webinar » 16:10
10/24/21
10/24
16:10
10/24/21
16:10
ASLN

Aslan Pharmaceuticals

$1.47 /

-0.12 (-7.55%)

Management discusses the…

Management discusses the recently announced, positive topline data from the Company's randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for treatment of moderate-to-severe atopic dermatitis (AD) in an Investor Webinar to be held on October 25 at 10 am. Webcast Link

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

Hot Stocks
Aslan Pharmaceuticals announces scientific collaboration for ASLAN04 biomarkers » 07:05
10/22/21
10/22
07:05
10/22/21
07:05
ASLN

Aslan Pharmaceuticals

$1.59 /

+0.03 (+1.92%)

ASLAN Pharmaceuticals…

ASLAN Pharmaceuticals announced a collaboration with renowned inflammatory skin disease expert Dr Emma Guttman-Yassky, MD PhD, to conduct research that will continue throughout ASLAN's Phase 2b program to identify and characterize the effects of ASLAN004 on disease-associated skin and serum-biomarkers in adults with moderate-to-severe atopic dermatitis. In the study, Dr Guttman-Yassky and her team will be evaluating a complex cadre of skin and serum biomarkers, including those from the T helper 2 and Th22 inflammatory pathways, known to play a critical role in the inflammation that is characteristic of AD. The study aims to provide insight into the cellular and molecular mechanisms of ASLAN004 that may correlate with clinical efficacy, by identifying the key biomarkers and pathways altered by ASLAN004 during the treatment period. Dr Karen Veverka, Vice President, Medical, ASLAN Pharmaceuticals, said: "We are fortunate to be collaborating with Dr Guttman-Yassky and her team for our Phase 2b trial of ASLAN004 in moderate-to-severe AD patients and we expect to enroll the first patient in this study later this quarter. Advancing our knowledge about the effects of ASLAN004 in patients, while developing a deeper understanding of its differentiation versus other pathway-specific treatments, is an important next step in our development of ASLAN004 as a potential best-in-class, novel treatment option."

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.59 /

+0.03 (+1.92%)

ASLN Aslan Pharmaceuticals
$1.59 /

+0.03 (+1.92%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.59 /

+0.03 (+1.92%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.59 /

+0.03 (+1.92%)

ASLN Aslan Pharmaceuticals
$1.59 /

+0.03 (+1.92%)

Hot Stocks
Aslan announces KOL event to discuss atopic dermatitis, ASLAN004 » 07:25
10/18/21
10/18
07:25
10/18/21
07:25
ASLN

Aslan Pharmaceuticals

$1.57 /

-0.035 (-2.18%)

ASLAN Pharmaceuticals…

ASLAN Pharmaceuticals announced it will host the first in a series of Key Opinion Leader events on the emerging atopic dermatitis treatment landscape, and a review of the recently announced, topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis. ASLAN004 is a potential first-in-class monoclonal antibody that targets the IL-13 receptor that has the potential for a differentiated profile in terms of convenience, safety and efficacy. Dr Jonathan Silverberg, MD PhD MPH, will be the first to speak at the series on Monday, October 25, 2021, at 10:00am ET. ASLAN's A4 Series: Aspects of Atopic Dermatitis and ASLAN004 will feature additional thought leaders in the subsequent months to discuss the evolving atopic dermatitis landscape.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.57 /

-0.035 (-2.18%)

ASLN Aslan Pharmaceuticals
$1.57 /

-0.035 (-2.18%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.57 /

-0.035 (-2.18%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.57 /

-0.035 (-2.18%)

ASLN Aslan Pharmaceuticals
$1.57 /

-0.035 (-2.18%)

Hot Stocks
Aslan Pharmaceuticals announces expansion of SAB » 07:04
10/14/21
10/14
07:04
10/14/21
07:04
ASLN

Aslan Pharmaceuticals

$1.65 /

+0.055 (+3.45%)

ASLAN Pharmaceuticals…

ASLAN Pharmaceuticals announced the appointments of Dr Melinda Gooderham, Dr Jacob Thyssen, and Associate Professor Peter Foley as members of its Scientific Advisory Board, SAB. The SAB, chaired by Dr Lawrence Eichenfield, was established in September following the appointment of Dr Eichenfield and Dr Eric Simpson. Gooderham is the Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research, Ontario, Canada. Dr Jacob Thyssen is Chief Consultant with the Department of Dermatology at Bispebjerg Hospital, Denmark. Associate Professor Peter Foley is Head, Dermatology Research, Department of Dermatology at St Vincent's Hospital, Melbourne.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.65 /

+0.055 (+3.45%)

ASLN Aslan Pharmaceuticals
$1.65 /

+0.055 (+3.45%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.65 /

+0.055 (+3.45%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.65 /

+0.055 (+3.45%)

ASLN Aslan Pharmaceuticals
$1.65 /

+0.055 (+3.45%)

On The Fly
Wall Street in Fives - Must Read Lists for Monday » 16:22
09/27/21
09/27
16:22
09/27/21
16:22
FB

Facebook; also tag MVRS

$353.62 /

+0.485 (+0.14%)

, BX

Blackstone

$123.33 /

-1.82 (-1.45%)

, MGM

MGM Resorts

$45.08 /

+0.455 (+1.02%)

, PSNY

Polestar

/

+

, GGPI

Gores Guggenheim

$10.46 /

+0.47 (+4.70%)

, GSK

GlaxoSmithKline

$38.49 /

+0.1 (+0.26%)

, VIR

Vir Biotechnology

$45.02 /

+1.13 (+2.57%)

, COIN

Coinbase

$232.29 /

+0.64 (+0.28%)

, RIDE

Lordstown Motors

$7.77 /

+0.205 (+2.71%)

, ABNB

Airbnb

$174.30 /

-1.605 (-0.91%)

, ATUS

Altice USA

$19.40 /

-1.2 (-5.83%)

, AMZN

Amazon.com

$3,406.70 /

-20.28 (-0.59%)

, GM

General Motors

$53.26 /

+1.035 (+1.98%)

, XLRN

Acceleron

$178.81 /

+11.29 (+6.74%)

, HUM

Humana

$400.86 /

+1.99 (+0.50%)

, GOOG

Alphabet

$2,830.94 /

-22.76 (-0.80%)

, GOOGL

Alphabet Class A

$2,821.88 /

-21.53 (-0.76%)

, AAPL

Apple

$145.39 /

-1.52 (-1.03%)

, TSLA

Tesla

$791.37 /

+16.75 (+2.16%)

, WFC

Wells Fargo

$47.55 /

-0.37 (-0.77%)

, RCAT

Red Cat

$3.59 /

+1.2 (+50.21%)

, ASPU

Aspen Group

$5.40 /

+0.3 (+5.88%)

, BBIG

Vinco Ventures

$6.98 /

+0.68 (+10.79%)

, ASLN

Aslan Pharmaceuticals

$2.11 /

-1.14 (-35.08%)

, CAPR

Capricor Therapeutics

$4.48 /

-0.7 (-13.51%)

, SPNE

SeaSpine

$15.25 /

-1.11 (-6.78%)

, IBIO

iBio

$1.14 /

-0.025 (-2.16%)

, PRMNF

Prime Mining

$3.31 /

+0.0105 (+0.32%)

, JKS

JinkoSolar

$44.00 /

+1.65 (+3.90%)

, PUYI

Puyi

$6.10 /

+0.09 (+1.50%)

Get caught up quickly on…

ShowHide Related Items >><<
XLRN Acceleron
$178.81 /

+11.29 (+6.74%)

WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

VIR Vir Biotechnology
$45.02 /

+1.13 (+2.57%)

TSLA Tesla
$791.37 /

+16.75 (+2.16%)

SPNE SeaSpine
$15.25 /

-1.11 (-6.78%)

RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

RCAT Red Cat
$3.59 /

+1.2 (+50.21%)

PSNY Polestar
/

+

PRMNF Prime Mining
$3.31 /

+0.0105 (+0.32%)

MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

JKS JinkoSolar
$44.00 /

+1.65 (+3.90%)

IBIO iBio
$1.14 /

-0.025 (-2.16%)

HUM Humana
$400.86 /

+1.99 (+0.50%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

GOOG Alphabet
$2,830.94 /

-22.76 (-0.80%)

GM General Motors
$53.26 /

+1.035 (+1.98%)

GGPI Gores Guggenheim
$10.46 /

+0.47 (+4.70%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

COIN Coinbase
$232.29 /

+0.64 (+0.28%)

CAPR Capricor Therapeutics
$4.48 /

-0.7 (-13.51%)

BX Blackstone
$123.33 /

-1.82 (-1.45%)

BBIG Vinco Ventures
$6.98 /

+0.68 (+10.79%)

ATUS Altice USA
$19.40 /

-1.2 (-5.83%)

ASPU Aspen Group
$5.40 /

+0.3 (+5.88%)

ASLN Aslan Pharmaceuticals
$2.11 /

-1.14 (-35.08%)

AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

09/24/21 BTIG
Etsy price target raised to $238 from $215 at BTIG
09/22/21 Morgan Stanley
Facebook blog post not signal of near-term ad revenue risk, says Morgan Stanley
09/22/21 BMO Capital
Facebook guidance unchanged, not much new on technical side, says BMO Capital
09/22/21 Baird
Facebook IDFA update largely consistent with industry checks, says Baird
BX Blackstone
$123.33 /

-1.82 (-1.45%)

09/13/21
Fly Intel: Top five analyst upgrades
09/13/21 BMO Capital
Carlyle Group upgraded to Outperform from Market Perform at BMO Capital
09/03/21 Evercore ISI
Gates Industrial initiated with an Outperform at Evercore ISI
08/12/21 TD Securities
WPT Industrial REIT downgraded to Hold from Buy at TD Securities
MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

09/24/21 Credit Suisse
As Macau locks down, Credit Suisse warns of downside risk to 2022 GGR estimates
09/22/21 Craig-Hallum
Craig-Hallum says DraftKings deal outcome 'unanimously negative for competitors'
09/21/21 Jefferies
Jefferies sees takeout value for Entain at least GBp 2,820 per share
09/14/21 Wells Fargo
MGM Resorts initiated with an Overweight at Wells Fargo
PSNY Polestar
/

+

GGPI Gores Guggenheim
$10.46 /

+0.47 (+4.70%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

09/20/21 UBS
GlaxoSmithKline price target lowered to 1,460 GBp from 1,540 GBp at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
VIR Vir Biotechnology
$45.02 /

+1.13 (+2.57%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
COIN Coinbase
$232.29 /

+0.64 (+0.28%)

09/28/21 JMP Securities
Coinbase initiated with an Outperform at JMP Securities
09/14/21 Piper Sandler
Coinbase recent selloff overdone, says Piper Sandler
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
08/24/21
Fly Intel: Top five analyst initiations
RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

09/27/21
Fly Intel: Top five analyst downgrades
09/27/21 BTIG
Lordstown Motors price target lowered to $10 from $20 at BTIG
09/26/21 Goldman Sachs
Lordstown Motors downgraded to Sell from Neutral at Goldman Sachs
09/16/21 BofA
BofA cuts Lordstown Motors to Underperform, halves price target to $5
ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

09/27/21
Fly Intel: Top five analyst initiations
09/27/21 JPMorgan
Airbnb initiated with a Neutral at JPMorgan
09/15/21 Tigress Financial
Airbnb shares going to $206 in 12 months, says Tigress Financial
09/13/21
Fly Intel: Top five analyst initiations
ATUS Altice USA
$19.40 /

-1.2 (-5.83%)

09/27/21 Raymond James
Altice USA downgraded to Market Perform on strategic shift at Raymond James
09/27/21 Credit Suisse
Credit Suisse downgrades Altice USA amid new investment strategy
09/27/21 Credit Suisse
Altice USA downgraded to Neutral from Outperform at Credit Suisse
AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

09/27/21 BofA
Roku selloff overdone as streaming lead remains, says BofA
09/27/21 Morgan Stanley
Morgan Stanley cuts Amazon target to $4,100 on rising wage pressure
09/24/21 Morgan Stanley
Vtex upgraded to Overweight from Equal Weight at Morgan Stanley
09/24/21 Oppenheimer
Opco downgrades Cloudflare amid competition from Amazon, Microsoft
GM General Motors
$53.26 /

+1.035 (+1.98%)

09/26/21 Goldman Sachs
General Motors price target lowered to $59 from $62 at Goldman Sachs
09/24/21 Citi
GM investor day could be 'significant positive catalyst,' says Citi
09/13/21 Barclays
General Motors price target lowered to $68 from $71 at Barclays
08/09/21 Jefferies
General Motors price target lowered to $53 from $68 at Jefferies
XLRN Acceleron
$178.81 /

+11.29 (+6.74%)

09/27/21 Cowen
Cowen thinks Acceleron talks leaked by hopeful buyer, sees $180/share as too low
09/27/21 RBC Capital
Acceleron price target raised to $179 from $113 at RBC Capital
08/05/21 Piper Sandler
Acceleron price target raised to $146 from $143 at Piper Sandler
07/19/21 Wolfe Research
Acceleron assumed with an Outperform at Wolfe Research
HUM Humana
$400.86 /

+1.99 (+0.50%)

09/27/21 SVB Leerink
SVB Leerink 'looking through the noise,' starts Humana at Outperform
09/27/21 SVB Leerink
Humana initiated with an Outperform at SVB Leerink
09/24/21 Piper Sandler
1Life Healthcare price target lowered to $37 from $55.50 at Piper Sandler
09/09/21 Cowen
Humana initiated with an Outperform at Cowen
GOOG Alphabet
$2,830.94 /

-22.76 (-0.80%)

09/17/21 Jefferies
Alphabet price target raised to $3,325 from $3,150 at Jefferies
09/13/21 Goldman Sachs
Alphabet Class A initiated with a Buy at Goldman Sachs
GOOGL Alphabet Class A
$2,821.88 /

-21.53 (-0.76%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

09/27/21 Credit Suisse
Apple iPhone 13 extended waits versus 12 cycle continue, says Credit Suisse
09/22/21 Tigress Financial
Apple price target raised to $198 from $182 at Tigress Financial
09/21/21 BofA
BofA says nationalist sentiment resurgence in China could hurt iPhone sales
TSLA Tesla
$791.37 /

+16.75 (+2.16%)

09/28/21 Credit Suisse
Credit Suisse expects Tesla Q3 deliveries of 225k-230k, upside limited by supply
09/28/21 Piper Sandler
Q3 will be Tesla's 'strongest quarter ever,' says Piper Sandler
09/23/21
Fly Intel: Top five analyst initiations
09/23/21 Tudor Pickering
Tudor Pickering starts 'fundamentally overvalued' Tesla at Sell
WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

09/28/21 JPMorgan
Wells Fargo selloff on DOJ settlement seems overdone, says JPMorgan
09/28/21 Morgan Stanley
Wells Fargo downgraded to Equal Weight at Morgan Stanley on asset cap drag
09/28/21 Morgan Stanley
Wells Fargo downgraded to Equal Weight from Overweight at Morgan Stanley
09/23/21 JPMorgan
Wells Fargo asset cap will be around for longer, says JPMorgan
RCAT Red Cat
$3.59 /

+1.2 (+50.21%)

06/07/21 ThinkEquity
Red Cat initiated with a Buy at ThinkEquity
ASPU Aspen Group
$5.40 /

+0.3 (+5.88%)

09/15/21 Craig-Hallum
Aspen Group price target lowered to $10 from $14 at Craig-Hallum
07/14/21 Canaccord
Aspen Group price target lowered to $13 from $14 at Canaccord
06/24/21 Canaccord
Aspen Group a good entry point following retreat from highs, says Canaccord
05/18/21 Roth Capital
Aspen Group risk/reward 'highly favorable,' says Roth Capital
BBIG Vinco Ventures
$6.98 /

+0.68 (+10.79%)

ASLN Aslan Pharmaceuticals
$2.11 /

-1.14 (-35.08%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
CAPR Capricor Therapeutics
$4.48 /

-0.7 (-13.51%)

SPNE SeaSpine
$15.25 /

-1.11 (-6.78%)

09/27/21 Stifel
SeaSpine second spine company to preview softer Q3, says Stifel
09/27/21 BTIG
SeaSpine price target lowered to $23 from $28 at BTIG
08/02/21 Piper Sandler
SeaSpine sales upside more than offset increased opex, says Piper Sandler
05/25/21 Canaccord
SeaSpine investors should add positions ahead of second-half, says Canaccord
IBIO iBio
$1.14 /

-0.025 (-2.16%)

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
PRMNF Prime Mining
$3.31 /

+0.0105 (+0.32%)

05/19/21 Stifel
Prime Mining initiated with a Buy at Stifel
JKS JinkoSolar
$44.00 /

+1.65 (+3.90%)

09/27/21 GLJ Research
JinkoSolar cut Q3 guidance with Friday's Jiangxi Jinko news, says GLJ Research
09/16/21 Roth Capital
JinkoSolar price target lowered to $51 from $58 at Roth Capital
09/16/21 GLJ Research
GLJ sees nearly 80% downside in JinkoSolar, cuts target to $10.70
08/13/21 GLJ Research
JinkoSolar shipment into U.S. stopped by customs, says GLJ Research
PUYI Puyi
$6.10 /

+0.09 (+1.50%)

XLRN Acceleron
$178.81 /

+11.29 (+6.74%)

WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

VIR Vir Biotechnology
$45.02 /

+1.13 (+2.57%)

TSLA Tesla
$791.37 /

+16.75 (+2.16%)

SPNE SeaSpine
$15.25 /

-1.11 (-6.78%)

RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

RCAT Red Cat
$3.59 /

+1.2 (+50.21%)

PUYI Puyi
$6.10 /

+0.09 (+1.50%)

PRMNF Prime Mining
$3.31 /

+0.0105 (+0.32%)

MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

JKS JinkoSolar
$44.00 /

+1.65 (+3.90%)

IBIO iBio
$1.14 /

-0.025 (-2.16%)

HUM Humana
$400.86 /

+1.99 (+0.50%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

GOOG Alphabet
$2,830.94 /

-22.76 (-0.80%)

GM General Motors
$53.26 /

+1.035 (+1.98%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

COIN Coinbase
$232.29 /

+0.64 (+0.28%)

BX Blackstone
$123.33 /

-1.82 (-1.45%)

BBIG Vinco Ventures
$6.98 /

+0.68 (+10.79%)

ATUS Altice USA
$19.40 /

-1.2 (-5.83%)

ASPU Aspen Group
$5.40 /

+0.3 (+5.88%)

ASLN Aslan Pharmaceuticals
$2.11 /

-1.14 (-35.08%)

AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

  • 24
    Aug
  • 19
    Jul
  • 30
    Apr
  • 16
    Apr
  • 14
    Apr
  • 03
    Mar
  • 08
    Dec
  • 10
    Dec
XLRN Acceleron
$178.81 /

+11.29 (+6.74%)

WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

TSLA Tesla
$791.37 /

+16.75 (+2.16%)

RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

HUM Humana
$400.86 /

+1.99 (+0.50%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

GOOG Alphabet
$2,830.94 /

-22.76 (-0.80%)

GM General Motors
$53.26 /

+1.035 (+1.98%)

GGPI Gores Guggenheim
$10.46 /

+0.47 (+4.70%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

COIN Coinbase
$232.29 /

+0.64 (+0.28%)

BX Blackstone
$123.33 /

-1.82 (-1.45%)

AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

XLRN Acceleron
$178.81 /

+11.29 (+6.74%)

WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

VIR Vir Biotechnology
$45.02 /

+1.13 (+2.57%)

SPNE SeaSpine
$15.25 /

-1.11 (-6.78%)

RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

RCAT Red Cat
$3.59 /

+1.2 (+50.21%)

MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

JKS JinkoSolar
$44.00 /

+1.65 (+3.90%)

IBIO iBio
$1.14 /

-0.025 (-2.16%)

HUM Humana
$400.86 /

+1.99 (+0.50%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

GOOG Alphabet
$2,830.94 /

-22.76 (-0.80%)

GM General Motors
$53.26 /

+1.035 (+1.98%)

GGPI Gores Guggenheim
$10.46 /

+0.47 (+4.70%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

COIN Coinbase
$232.29 /

+0.64 (+0.28%)

BX Blackstone
$123.33 /

-1.82 (-1.45%)

BBIG Vinco Ventures
$6.98 /

+0.68 (+10.79%)

ATUS Altice USA
$19.40 /

-1.2 (-5.83%)

ASPU Aspen Group
$5.40 /

+0.3 (+5.88%)

AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

WFC Wells Fargo
$47.55 /

-0.37 (-0.77%)

TSLA Tesla
$791.37 /

+16.75 (+2.16%)

RIDE Lordstown Motors
$7.77 /

+0.205 (+2.71%)

MGM MGM Resorts
$45.08 /

+0.455 (+1.02%)

JKS JinkoSolar
$44.00 /

+1.65 (+3.90%)

IBIO iBio
$1.14 /

-0.025 (-2.16%)

GSK GlaxoSmithKline
$38.49 /

+0.1 (+0.26%)

GOOGL Alphabet Class A
$2,821.88 /

-21.53 (-0.76%)

GM General Motors
$53.26 /

+1.035 (+1.98%)

GGPI Gores Guggenheim
$10.46 /

+0.47 (+4.70%)

FB Facebook; also tag MVRS
$353.62 /

+0.485 (+0.14%)

COIN Coinbase
$232.29 /

+0.64 (+0.28%)

BX Blackstone
$123.33 /

-1.82 (-1.45%)

BBIG Vinco Ventures
$6.98 /

+0.68 (+10.79%)

ATUS Altice USA
$19.40 /

-1.2 (-5.83%)

ASPU Aspen Group
$5.40 /

+0.3 (+5.88%)

ASLN Aslan Pharmaceuticals
$2.11 /

-1.14 (-35.08%)

AMZN Amazon.com
$3,406.70 /

-20.28 (-0.59%)

ABNB Airbnb
$174.30 /

-1.605 (-0.91%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

AAPL Apple
$145.39 /

-1.52 (-1.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.